India's Piramal Pharma rises after Goldman Sachs initiates with "buy"

Piramal Pharma (Mumbai)

08/04/2025 07:34

** Shares of Piramal Pharma PIRM.NS rise about 2.5% to 222.29 rupees apiece after Goldman Sachs starts coverage with   "buy" rating

** PIRM shares are down 5.7% in the last two sessions amid a broader market drop after the U.S. announced reciprocal tariffs

** Goldman Sachs sets a target price for PIRM at 275 rupees, implying a potential upside of 26.8% in the next 12 months

** PIRM is well-placed to deliver a top-quartile profit growth over the fiscal years 2024-2028, says Goldman Sachs

** Forecasts PIRM to post sustainable growth in contract development and manufacturing segment, capacity ramp-ups, and domestic consumer healthcare businesses

** PIRM shares are down 18.5% in 2025 so far mirroring the small-cap index .NIFSMCP100 of which it is a constituent

 (Reporting by Bharath Rajeswaran in Bengaluru)

 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))